In this report, we provide evidence that dEGFR39 has excellent performance, which is not only useful to screen EGFR-targeted mutations from plasma of NSCLC patients to guide targeted therapy, but also to evaluate prognosis after treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.